J Am Coll Cardiol. 2021 Feb 2;77(4):450-500. doi: 10.1016/j.jacc.2020.11.035. Epub 2020 Dec 17.
This executive summary of the valvular heart disease guideline provides recommendations for clinicians to diagnose and manage valvular heart disease as well as supporting documentation to encourage their use.
A comprehensive literature search was conducted from January 1, 2010, to March 1, 2020, encompassing studies, reviews, and other evidence conducted on human subjects that were published in English from PubMed, EMBASE, Cochrane, Agency for Healthcare Research and Quality Reports, and other selected database relevant to this guideline.
Many recommendations from the earlier valvular heart disease guidelines have been updated with new evidence and provides newer options for diagnosis and treatment of valvular heart disease. This summary includes only the recommendations from the full guideline which focus on diagnostic work-up, the timing and choice of surgical and catheter interventions, and recommendations for medical therapy. The reader is referred to the full guideline for graphical flow charts, text, and tables with additional details about the rationale for and implementation of each recommendation, and the evidence tables detailing the data considered in developing these guidelines.
本瓣膜性心脏病指南执行摘要为临床医生提供了诊断和治疗瓣膜性心脏病的建议,并提供了支持性文件以鼓励他们使用。
从 2010 年 1 月 1 日至 2020 年 3 月 1 日,进行了全面的文献检索,涵盖了在 PubMed、EMBASE、Cochrane、医疗保健研究和质量报告机构以及与本指南相关的其他选定数据库中发表的关于人类受试者的研究、综述和其他证据,均为英文。
许多早期瓣膜性心脏病指南中的建议都已根据新证据进行了更新,并为瓣膜性心脏病的诊断和治疗提供了更新的选择。本摘要仅包含完整指南中的建议,重点是诊断检查、手术和导管介入的时机和选择,以及药物治疗的建议。读者可参考完整指南中的图形流程图、文本和表格,了解每个建议的理由和实施情况,以及详细介绍制定这些指南时考虑的数据的证据表。